CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
BackgroundIn clinical applications of CAR T-cell therapy, life-threatening adverse events including cytokine release syndrome and neurotoxicity can lead to treatment failure. Outcomes of patients treated with anti-CD30 CAR T- cell have been disappointing in relapsing/refractory (r/r) classical Hodgk...
Main Authors: | YuanBo Xue, Xun Lai, RuiLei Li, ChunLei Ge, BaoZhen Zeng, Zhen Li, QiaoFen Fu, LiuFang Zhao, SuWei Dong, JinYan Yang, JiYin Guo, QingYin Meng, QingHua Tan, ZhenHui Li, HaiYan Ding, YanLei Zhang, ShaoHui Liu, Alex H. Chang, Hong Yao, RongCheng Luo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.607362/full |
Similar Items
-
The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt
by: Osama Mohamed, et al.
Published: (2020-02-01) -
Expression of CD40 and CD40L in Gastric Cancer Tissue and Its Clinical Significance
by: Rui Li, et al.
Published: (2009-09-01) -
Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B‐cell lymphoma
by: Xiao‐bo Ma, et al.
Published: (2018-09-01) -
What Else Can CD39 Tell Us?
by: Hai Zhao, et al.
Published: (2017-06-01) -
Level of Foxp3, DNMTs, methylation of Foxp3 promoter region, and CD4 + CD25 + CD127low regulatory T cells in vulvar lichen sclerosus
by: Lin Wang, et al.
Published: (2021-06-01)